Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)
Funding Agency:
- National Institutes of Health
The purpose of the Stephen I. Katz Early Stage Investigator Research Project Grant is to provide a new pathway for Early Stage Investigators (ESIs) who wish to propose research projects in a new direction for which preliminary data do not exist. Named in honor of the late National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Director, Stephen I. Katz, M.D., Ph.D., this notice of funding opportunity (NOFO) is open to a broad range of scientific research relevant to the mission of the participating NIH Institutes and Centers (ICs). Proposed projects must represent a change in research direction for the ESI and should be innovative and unique. A distinct feature for this NOFO is that applications must not include preliminary data. PD/PI's who wish to propose research projects consistent with their past work or training and/or supported by preliminary data, should apply to the Parent R01 or other NOFOs allowing for preliminary data. More information and FAQs are available on the Katz award program website .Katz award was created in 2020 to provide a unique opportunity for early-stage investigators to take their research in a completely new direction, thereby stimulating innovation and encouraging new approaches to solving problems. Consistent with NIH’s commitment to enhance workforce diversity, researchers from diverse backgrounds , including individuals from underrepresented racial and ethnic groups, individuals with disabilities, individuals from disadvantaged backgrounds, and women are strongly encouraged to work with their institutions to develop applications for this funding opportunity. For more information, see NOT-OD-20-031: Notice of NIH’s Interest in Diversity. This NOFO is appropriate for ESIs who wish to initiate a research project in an area different from their previous research focus and/or training experience, and therefore have not produced preliminary data. Proposed research projects can rely on the PD/PI’s prior work and expertise as its foundation, but must not be an incremental advancement, expansion, or extension of a previous research effort. The change in research direction could involve, for example, a new approach, methodology, technique, discipline, therapeutic target, and/or new paradigm, different from the ESI’s previous research efforts. Importantly, the proposed direction must represent a change in research direction for the PD/PI. Because a change in research direction is heavily dependent upon the area of investigation, potential applicants are strongly encouraged to contact a program director to discuss their proposed project. If the application proposes multiple Principal Investigators (MPIs), all PD/PIs must be ESIs and the research direction must be a change in research direction for all MPIs. Please note that the application must describe how the proposed new research direction is different from the ESI’s past work in a separate attachment entitled New Research Directions (see Section IV, SF424(R&R) Other Project Information).
For this funding opportunity, applications including preliminary data will be considered noncompliant with the NOFO instructions and will be withdrawn. Preliminary data are defined as data not yet published. Existence of preliminary data is an indication that the proposed project has advanced beyond the scope defined by this program and makes the application unsuitable for this funding opportunity. Publication in the proposed new research direction is an indication that the proposed work may not be in a new research direction for the ESI. The logical basis and premise for the proposed work should be supported by published data or data from preprints that may have a Digital Object Identifier (DOI). These data must be labeled and cited adjacent to each occurrence within the application and must be presented unmodified from the original published format. Figures and tables containing data must include citation(s) within the legend. The data should be unambiguously identified as published through citation that, if available, includes the DOI (see Section IV.2). Prospective applicants are reminded that NIH instructions do not allow URLs or hyperlinks to websites or documents that contain data in any part of the application (see NOT-OD-20-174).
Determinations of merit and feasibility will consider the conceptual framework, level of innovation, and potential to significantly advance our knowledge and understanding. Applicants are encouraged to justify the conceptual and technical feasibility for the proposed work through previous experience, literature citations, compelling logic, and published data and publicly available databases. Examples of sources which can be used to demonstrate feasibility (non-inclusive) include PubMed; Bookshelf; Medline Plus; Open-I; TOXNET; ClinicalTrials.gov; BLAST; Nucleotide; Genome; SNP; Gene; Protein; and PubChem. Since applications to this NOFO could involve higher risk, applicants are encouraged to clearly explain the significance of the proposed work, to allow the reviewers to determine whether the potential impact offsets a higher risk. Applicants should clearly explain why the new knowledge to be gained is beyond incremental.
Research grant applications are assigned to participating ICs based on receipt and referral guidelines and applications may be assigned to multiple participating ICs with related research interests. Applicants are encouraged to identify a participating IC that supports their area of research via the Table of IC-Specific Information, Requirements and Staff Contacts to inquire about the IC's interest in supporting the proposed research project.
Note: This Notice of Funding Opportunity (NOFO) does not accept applications proposing clinical trials.
Application budgets are not limited but need to reflect the actual needs of the proposed project.
May 29, 2024
Lindsey Nicole Friend
NIDA - NATIONAL INSTITUTE ON DRUG ABUSE
Phone: none
E-mail: lindsey.friend@nih.gov
Scott Rogers
National Cancer Institute (NCI)
Telephone: 240-276-6932
Email: rogerssc@mail.nih.gov